FDA grants Orphan Drug Designation to Hutchmed’s sovleplenib for primary ITP
The U.S. Food and Drug Administration awarded Orphan Drug Designation to Hutchmed’s oral Syk inhibitor sovleplenib for the treatment of primary immune thrombocytopenia (ITP). The designation makes the drug eligible for up to seven years of U.S. market exclusivity if approved, along with tax credits and user‑fee waivers. Hutchmed also noted that new drug applications for sovleplenib are under review in China for ITP and another autoimmune indication. The announcement was followed by a modest decline in Hutchmed’s share price.
Why it matters
The exclusivity incentive could significantly increase future revenue potential for sovleplenib, according to Hutchmed’s press release. The stock fell 3.48% to $13.32 at market close, reflecting immediate market reaction.
Key facts
- 1The FDA granted Orphan Drug Designation to sovleplenib for primary immune thrombocytopenia. stocktitan.net
- 2If approved, the drug would be eligible for seven years of U.S. market exclusivity. stocktitan.net
- 3Hutchmed estimates about 56,000 people in the U.S., Europe and Japan have primary ITP. rttnews.com
- 4Hutchmed estimates around 110,000 people in China have primary ITP. rttnews.com
- 5HCM closed Wednesday’s trading at $13.32, down 3.48%. rttnews.com
- 6During overnight trading the stock was at $13.42, up 0.75%. rttnews.com
Summary written by AlphAI AI Desk from 2 of 2 sources. Not investment advice. Figures are as stated by the linked sources.